GOP Hemp Bill's White House Backing Claim Runs Into Inhalable Product Snag

Photo by Ramaz Bluashvili via Pexels.

Sixty pages is a lot of legislative real estate for a bill about hemp, and Reps. Andy Barr (R-KY) and Angie Craig (D-MN) have used most of it trying to solve a problem Congress created for itself back in 2018: how do you write a definition of hemp that doesn't accidentally outlaw half the products currently sitting on dispensary and gas station shelves. Their bill would let a wide swath of hemp-derived goods currently sold to adults 21 and older keep operating, provided they meet a new set of federal rules. Barr's office has been telling reporters, including The Hill, that the White House is behind the bill. That's a useful thing to say if you're trying to build momentum for a floor vote.

But when a White House official was asked directly about it, the answer wasn't an endorsement of Barr's text. It was a pointer back to two things Trump has already said publicly: a December executive order on marijuana rescheduling and Medicare coverage of CBD, and an April Truth Social post noting that more must be done. Neither of those is the same as saying this bill, as written, has our support. That gap is the whole story here. Is this genuinely a White House-blessed compromise, or is Barr getting out ahead of an administration that still has real objections, particularly around how the bill treats inhalable hemp products like vapes and smokable flower?

What the Barr-Craig Bill Would Actually Do

Photo by Nothing Ahead via Pexels.

The core of the Barr-Craig bill is a rewrite of what counts as legal hemp. Since the 2018 Farm Bill, hemp has been defined as cannabis containing no more than 0.3 percent THC on a dry-weight basis, a threshold that never accounted for the fact that modern extraction and infusion techniques can pack meaningful amounts of THC into a product while still technically staying under that line when measured against the plant's dry weight. Barr and Craig's bill would raise that ceiling to 1 percent total THC, a more than threefold increase that would immediately legalize a lot of products currently existing in a gray or arguably illegal zone.

The bill also creates a new regulatory category under the Federal Food, Drug, and Cosmetic Act called a hemp-derived consumable product, which is broad enough to sweep in drinks, gummies and other ingestibles, oral tinctures, sublingual strips, capsules, tablets, inhalable products such as vapes and smokable flower, and topicals and transdermals like lotions and patches. For each of those categories, the bill sets default potency limits that kick in automatically if the HHS secretary doesn't establish separate rules: 5 milligrams of THC per serving for oral products, and 50 milligrams per serving for both inhalables and topicals.

This isn't Barr's first swing at this. Earlier versions of similar language were attached as amendments to larger must-pass bills, only to get stripped out or blocked from floor consideration by the House Rules Committee, which controls what amendments actually get a vote. Filing this as a standalone 60-page bill is Barr's attempt to give the policy enough weight and detail to survive that kind of procedural gatekeeping this time around.

The White House Endorsement Claim Doesn't Quite Hold Up

Photo by Olek Buzunov via Unsplash.

Barr's office has framed this bill to reporters as something the White House has already signed off on. That's a strong claim, and it's worth being precise about what the administration has actually said on the record, because it's considerably softer. A White House official pointed not to Barr's bill specifically but to Trump's December executive order directing federal agencies to expedite marijuana rescheduling and extend Medicare coverage to CBD, calling that the administration's definitive position. The official also cited an April Truth Social post from Trump saying more must be done on hemp and cannabis policy, which is a general statement of intent, not a line-by-line endorsement of the Barr-Craig language.

The most telling piece of evidence, though, is language from the Office of Management and Budget itself. In a written statement on the bill, OMB said the administration supports advancement of this legislation, but looks forward to addressing its concerns prior to enactment. Read that sentence carefully and it's not an endorsement so much as a conditional green light with an asterisk. Support for moving something forward is not the same as support for passing it as written, and the phrase addressing its concerns prior to enactment is bureaucratic shorthand for we still have problems with this.

That distinction matters enormously for how this bill gets covered and how it gets negotiated on the Hill. If lawmakers and industry groups treat this as White House-approved, they may be less inclined to push for changes. The actual record suggests the administration is still negotiating, and Barr's messaging may be doing more work to build political momentum than the facts currently support.

Inhalable Products Are Where the Administration Balks

Photo by Jonathan Cooper via Pexels.

Sources familiar with the administration's thinking say the sticking point isn't the bill's basic framework or even the 1 percent THC threshold, it's specifically how the legislation handles inhalable hemp products. That includes vape cartridges and smokable hemp flower, both of which have drawn sustained skepticism from public health officials and FDA staff for years, largely because they're harder to regulate for consistent dosing and easier for underage users to access than a bottled beverage or a tincture sold behind a counter.

The bill's own numbers illustrate why this is a fair target for concern. Oral products get capped at a default 5 milligrams per serving, a relatively conservative limit similar to what many state cannabis programs already use for low-dose edibles. Inhalables, by contrast, get lumped in with topicals at a default 50 milligrams per serving, ten times higher than the oral cap. Since inhaled THC hits the bloodstream much faster and more efficiently than something swallowed, pairing a high potency allowance with a delivery method known for rapid intoxication is exactly the kind of detail that tends to trigger pushback from agencies focused on youth access and public health.

It's worth noting the administration hasn't been hostile to Barr's efforts generally. Back in April, Domestic Policy Council director Vince Haley and legislative affairs aide James Braid sent Barr's office a set of suggested changes, framing it as an appreciation for his work advancing the executive order's CBD access goals. That kind of engagement, offering edits rather than walking away, suggests the current friction over inhalables is a specific and possibly fixable disagreement rather than a sign the whole bill is dead on arrival.

Why the Clock Is Running Out

Photo by NickyPe via Pixabay.

None of this negotiating happens in a vacuum, because there's already a hard deadline baked into existing law. Come November 12, 2026, a set of rules take effect that would ban hemp products containing more than 0.4 milligrams of total THC per container, a threshold so low it would sweep up the overwhelming majority of THC-infused beverages, gummies, and vapes currently sold nationwide, regardless of how they're marketed or dosed.

That same deadline redefines hemp itself to mean cannabis containing no more than 0.3 percent total THC when THCA is counted alongside delta-9 THC, closing a loophole that's let a huge share of the hemp industry operate on the argument that THCA doesn't count until it's heated. It also would outlaw synthesized cannabinoids like delta-8 THC, along with novel compounds such as HHC that don't occur naturally in the plant in meaningful quantities. Put simply, without new legislation signed into law before that date, a large chunk of what's currently sitting on convenience store and smoke shop shelves becomes illegal overnight, no enforcement discretion required.

That's the pressure Barr and Craig are racing against, and it's not just a House problem. Sen. Tim Sheehy (R-MT) has already said a companion bill is coming in the Senate, which means the House needs to settle its own internal disagreements, inhalables very much included, before there's even a stable text to negotiate against on the other side of the Capitol. The clock doesn't care whether the White House's support is firm or conditional.

The fight over inhalables isn't a footnote to this bill, it's arguably the whole ballgame for a big chunk of the hemp industry. Vapes and smokable flower are exactly the product categories most exposed under the current 2026 deadline, and they're also the categories the administration appears least comfortable handing a generous 50 milligram default cap. How that specific provision gets resolved, whether it's lowered, restructured, or left to HHS rulemaking, will likely determine whether entire product lines survive next November or disappear from shelves regardless of what else the bill accomplishes.

Barr's claim of White House backing reads less like a confirmed fact and more like a lawmaker trying to shape the narrative before the details are locked down. The OMB language, supports advancement but looks forward to addressing concerns, all but says as much itself. That's not an unusual move in Washington, framing an unfinished negotiation as a done deal to build pressure for a floor vote, but it's worth readers keeping that distinction in mind rather than assuming this bill has already cleared its biggest political hurdle.

For anyone actually operating in or buying from the hemp market, the practical takeaway is to keep an eye on how the potency caps evolve in committee rather than assuming any current product is safe under a future federal standard. It's also worth remembering that federal law is only part of the picture. Several states already impose THC limits, product bans, or age restrictions well beyond what the current federal framework requires, so checking your own state's hemp statutes remains just as important as watching what happens in Washington. Nothing here should be taken as legal advice, and rules are shifting fast enough that today's compliant product could be tomorrow's liability.